<DOC>
	<DOCNO>NCT00407862</DOCNO>
	<brief_summary>Inhibition RAS delay onset diabetes clinical study . Preliminary evidence suggest telmisartan may unique metabolic property compare ARB due activation PPARγ . This test comparison ARB metabolically neutral already publish study . H0 : Telmisartan different Losartan respect metabolic vascular effect . H1 : Telmisartan different Losartan respect metabolic vascular effect .</brief_summary>
	<brief_title>Telmisartan Losartan Hypertensive IGT</brief_title>
	<detailed_description>Background : Both , ACE-inhibitors well angiotensin-II-type-1 ( AT1 ) receptor antagonists seem reduce development type-II diabetes patient hypertension and/or high vascular risk ( 1-3 ) . The major drawback evidence derive post-hoc analysis study rather poor metabolic phenotypisation population include . Additionally , evidence base measurement fast plasma glucose . In subject impaired glucose tolerance ( IGT ) , insulin resistance dysfunction pancreatic beta-cells ( variable contribution ) already establish increase postprandial hyperglycemia consecutively increase cardiovascular risk ( 4 , 5 ) . In addition considerable risk future development manifest type-II diabetes range 3-6 % within year ( 6 , 7 ) . In patient prevention diabetes may also result cardiovascular prevention . As subject IGT often exhibit less pronounced metabolic syndrome , hypertension frequently find comorbidity vice versa IGT frequent hypertensive patient suggest possible common soil two disease ( 8 ) . Given evidence , hypertensive subject IGT suitable target population study metabolic vascular effect angiotensin-II-type-1-receptor antagonist . Finally , acknowledge insulin resistance need see context proinflammatory change metabolic syndrome , endothelial dysfunction associate possibly central role adipocyte ( Fig . 1 ) . Within context , hypothesis put forward blockade angiotensin system might prevent type-II diabetes via effect fat cell ( 9 ) . Rationale : The effect different angiotensin-II-type-1-receptor antagonist insulin sensitivity investigate various study different , either positive ( 10 ) negative ( 11 , 12 ) result in-depht investigation detail metabolic vascular effect perform . Telmisartan angiotensin-II-type-1-receptor antagonist recently describe possess specific property partial activator PPARγ ( 13 ) . This effect find comparable compunds losartan . Genes expression control receptor centrally involved pathology metabolic syndrome outline activation receptor result improve insulin sensitivity , ameliorate endothelial dysfunction , reduce inflammation potentially preserve beta-cell function ( review see ( 14 ) ) . Therefore , telmisartan candidate might possess specific beneficial property addition antihypertensive effect . Objective : To compare metabolic vascular effect telmisartan metoprolol hypertensive patient IGT .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>IGT accord criterion WHO standardise office blood pressure &gt; 140/90 mmHG treat hypertension 40 75 year age sign informed consent know hypersensitivity towards telmisartan losartan concommitant treatment ACEinhibitors BMI &gt; 35 kg/m2 inability perform selfcontrol blood pressure acute coronary syndrome cerebrovascular event within last 3 month Revascularisation within last 3 month heart failure &gt; NYHA 2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>insulin resistance</keyword>
	<keyword>beta cell function</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>